2024

Khalaf, A. et al. (2024) Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia. Science Translational Medicine, 16(751), eadi5336. (doi: 10.1126/scitranslmed.adi5336) (PMID:38865484)

2023

Papalazarou, V. et al. (2023) Phenotypic profiling of solute carriers characterises serine transport in cancer. Nature Metabolism, 5, pp. 2148-2168. (doi: 10.1038/s42255-023-00936-2) (PMID:38066114) (PMCID:PMC10730406)

Papalazarou, V. et al. (2023) Phenotypic profiling of solute carriers characterizes serine transport in cancer. Nature Metabolism, 5(12), pp. 2148-2168. (doi: 10.1038/s42255-023-00936-2) (PMID:38066114) (PMCID:PMC10730406)

2021

Nacke, M. et al. (2021) An ARF GTPase module promoting invasion and metastasis through regulating phosphoinositide metabolism. Nature Communications, 12, 1623. (doi: 10.1038/s41467-021-21847-4) (PMID:33712589) (PMCID:PMC7955138)

2020

Rushworth, L. K., Hewit, K., Munnings-Tomes, S., Somani, S., James, D., Shanks, E., Dufès, C., Straube, A., Patel, R. and Leung, H. Y. (2020) Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. British Journal of Cancer, 122, pp. 517-527. (doi: 10.1038/s41416-019-0681-5) (PMID:31844184) (PMCID:PMC7028732)

2019

Neidler, S. et al. (2019) Identification of a clinically relevant signature for early progression in KRAS-driven lung adenocarcinoma. Cancers, 11(5), 600. (doi: 10.3390/cancers11050600) (PMID:31032816) (PMCID:PMC6562816)

2018

Román-Fernández, Á. , Roignot, J., Sandilands, E., Nacke, M., Mansour, M. A., McGarry, L., Shanks, E., Mostov, K. E. and Bryant, D. M. (2018) The phospholipid PI(3,4)P2 is an apical identity determinant. Nature Communications, 9, 5041. (doi: 10.1038/s41467-018-07464-8) (PMID:30487552) (PMCID:PMC6262019)

2016

Peck, B. et al. (2016) Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer and Metabolism, 4(1), 6. (doi: 10.1186/s40170-016-0146-8) (PMID:27042297) (PMCID:PMC4818530)

Articles

Khalaf, A. et al. (2024) Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia. Science Translational Medicine, 16(751), eadi5336. (doi: 10.1126/scitranslmed.adi5336) (PMID:38865484)

Papalazarou, V. et al. (2023) Phenotypic profiling of solute carriers characterises serine transport in cancer. Nature Metabolism, 5, pp. 2148-2168. (doi: 10.1038/s42255-023-00936-2) (PMID:38066114) (PMCID:PMC10730406)

Papalazarou, V. et al. (2023) Phenotypic profiling of solute carriers characterizes serine transport in cancer. Nature Metabolism, 5(12), pp. 2148-2168. (doi: 10.1038/s42255-023-00936-2) (PMID:38066114) (PMCID:PMC10730406)

Nacke, M. et al. (2021) An ARF GTPase module promoting invasion and metastasis through regulating phosphoinositide metabolism. Nature Communications, 12, 1623. (doi: 10.1038/s41467-021-21847-4) (PMID:33712589) (PMCID:PMC7955138)

Rushworth, L. K., Hewit, K., Munnings-Tomes, S., Somani, S., James, D., Shanks, E., Dufès, C., Straube, A., Patel, R. and Leung, H. Y. (2020) Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. British Journal of Cancer, 122, pp. 517-527. (doi: 10.1038/s41416-019-0681-5) (PMID:31844184) (PMCID:PMC7028732)

Neidler, S. et al. (2019) Identification of a clinically relevant signature for early progression in KRAS-driven lung adenocarcinoma. Cancers, 11(5), 600. (doi: 10.3390/cancers11050600) (PMID:31032816) (PMCID:PMC6562816)

Román-Fernández, Á. , Roignot, J., Sandilands, E., Nacke, M., Mansour, M. A., McGarry, L., Shanks, E., Mostov, K. E. and Bryant, D. M. (2018) The phospholipid PI(3,4)P2 is an apical identity determinant. Nature Communications, 9, 5041. (doi: 10.1038/s41467-018-07464-8) (PMID:30487552) (PMCID:PMC6262019)

Peck, B. et al. (2016) Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer and Metabolism, 4(1), 6. (doi: 10.1186/s40170-016-0146-8) (PMID:27042297) (PMCID:PMC4818530)